2024-05-132024-05-132020Belvis Jiménez, M.I., Pino Bellido, P.d., Castro Laria, L., Maldonado Pérez, M.B., Sáez Díaz, A., Caunedo Álvarez, Á. y Argüelles Arias, F. (2020). Vedolizumab response in inflammatory bowel disease. Two years of follow-up. Revista Española de Enfermedades Digestivas, 112 (7), 555-558. https://doi.org/10.17235/reed.2020.7130/2020.1130-01082340-4167https://hdl.handle.net/11441/158235Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. Methods: this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. Results: fifty-five patients were included. Clinical remis sion rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. Conclusions: vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn’s disease and ulcerative colitis.application/pdf4 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/VedolizumabResponseRemissioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.17235/reed.2020.7130/2020